Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ANIX

Anixa Biosciences

ANIX Lead: Phase 1 ★ Read the deep dive → 2 Biotech Distilled articles ↓ 16 filings & releases ↓ Cash $1.4M (Jul 31, 2026) ↓ 2 verdicts ↓
Oncology CellProtein

Market cap $111M 34.8M shares (10-Q, Sep 9, 2026) × $3.18 close Nov 6, 2026

Most recent annual filing: 2026-01-12

Pipeline (3 active programs)

Capital (as filed)

Cash
$1.4M cash and cash equivalents · Jul 31, 2026 (10-Q)
Short-term investments
$12.5M Jul 31, 2026
Operating cash flow
−$1.8M quarter Apr 30, 2026 → Jul 31, 2026, year-to-date difference (10-Q)
As stated in coverage
$13.7M cash per the deep dive of Jul 30, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (2)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (2 calls)

Every verdict Biotech Distilled has published on Anixa Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-07-31 Watch Anixa Biosciences (ANIX) — Scientific Deep Dive for Lira-cel, the α-Lactalbumin Vaccine, and Pipeline Products FSHR biology is legitimate but the survival narrative is benchmarked against a comparator wrong by a factor of three to four, no objective response has been reported in four years, and structural dilution risks remain; wait for RECIST-confirmed responses from cohorts 5–7 with denominators.
  2. 2026-10-06 Watch UPDATE: Anixa Biosciences (ANIX) - Stable Is Not a Response Cohort 5 produced only one stable-disease result (not an objective response) and no DLTs, modestly de-risking safety but leaving efficacy and pharmacodynamics unproven; Watch List maintained pending RECIST-confirmed responses with denominators.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (16)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 18, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →